Finerenone

Cat. No.:	HY-111372		
CAS No.:	1050477-31	0	
Molecular Formula:	$C_{21}H_{22}N_4O_3$		
Molecular Weight:	378.42		
Target:	Mineralocorticoid Receptor		
Pathway:	Metabolic E	nzyme/P	rotease; Vitamin D Related/Nuclear Receptor
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month


SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.6426 mL	13.2128 mL	26.4257 mL		
		5 mM	0.5285 mL	2.6426 mL	5.2851 mL		
		10 mM	0.2643 mL	1.3213 mL	2.6426 mL		
	Please refer to the so	lubility information to select the ap	propriate solvent.				
Solubility: ≥ 2 2. Add each solv Solubility: ≥ 1 3. Add each solv	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.50 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.93 mg/mL (5.10 mM); Clear solution						
		ent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) 93 mg/mL (5.10 mM); Clear solution					

BIOLOGICAL ACTIV	
Description	Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC ₅₀ =18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease ^{[1][2]} .
In Vivo	Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frömter (MWF) rat ^[1] .

Product Data Sheet





Animal Model:	Twelve-week-old MWF rat ^[1]	
Dosage:	10 mg/kg	
Administration:	P.o.; daily for 4 weeks	
Result:	Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.	
Animal Model:	Twelve-week-old MWF rat ^[1]	
Dosage:	10 mg/kg	
Administration:	P.o.; daily for 4 weeks	
Result:	Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminu in the MWF model.	

CUSTOMER VALIDATION

• Nature. 2023 Feb;614(7947):326-333.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403.

[2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA